Reduce neutropenia by changing the date of eflapegrastim administration in breast cancer patients who have experienced neutropenia after chemotherapy
- Conditions
- Neoplasms
- Registration Number
- KCT0008416
- Lead Sponsor
- Eunseong Medical Foundation Good Gang-an Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Female
- Target Recruitment
- 100
Women aged 18 to 75 years old as of the date of study registration.
Patients with histologically confirmed invasive adenocarcinoma.
Patients with confirmed estrogen receptor, progesterone receptor, and Her2 receptor status.
Patients with ECOG performance status 0-1.
Patients with a left ventricular ejection fraction (LVEF) =55%.
Patients who have agreed to participate in this trial and have provided written consent.
Patients with a history of breast cancer treatment
Patients with a history of chemotherapy, radiation therapy, immunotherapy, or biotherapy for malignancies other than breast cancer
Patients with infectious diseases
Patients with serious illnesses that may affect this clinical trial: cardiovascular disease, kidney disease, liver disease, endocrine disease, tumors, or diabetes
Other individuals deemed by the clinical trial investigators to be unable to participate in the trial.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence rate of severe neutropenia
- Secondary Outcome Measures
Name Time Method duration of severe neutropenia;Incidence rate of febrile neutropenia;incidene rate of neutropenia related death